Q4 Earnings Forecast for Annovis Bio Issued By HC Wainwright

Annovis Bio, Inc. (NYSE:ANVS) – Research analysts at HC Wainwright cut their Q4 2024 earnings per share estimates for Annovis Bio in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.38) for the quarter, down from their previous forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Annovis Bio’s current full-year earnings is ($2.19) per share. HC Wainwright also issued estimates for Annovis Bio’s Q1 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.57) EPS, Q4 2025 earnings at ($0.76) EPS and FY2025 earnings at ($2.32) EPS.

A number of other equities analysts have also weighed in on the company. Maxim Group raised Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a research note on Friday, October 25th. EF Hutton Acquisition Co. I raised shares of Annovis Bio to a “strong-buy” rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Annovis Bio presently has an average rating of “Buy” and an average price target of $32.17.

Annovis Bio Stock Performance

Shares of ANVS stock opened at $6.84 on Thursday. The stock has a fifty day simple moving average of $8.43 and a two-hundred day simple moving average of $8.26. The firm has a market capitalization of $94.37 million, a PE ratio of -1.53 and a beta of 1.70. Annovis Bio has a 52-week low of $4.53 and a 52-week high of $22.49.

Annovis Bio (NYSE:ANVS) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.97) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.33).

Institutional Trading of Annovis Bio

A number of large investors have recently added to or reduced their stakes in the company. State Street Corp grew its holdings in shares of Annovis Bio by 23.7% in the third quarter. State Street Corp now owns 36,035 shares of the company’s stock valued at $290,000 after purchasing an additional 6,900 shares in the last quarter. Quest Partners LLC purchased a new stake in Annovis Bio during the third quarter valued at $371,000. Greenwich Wealth Management LLC lifted its position in Annovis Bio by 9.3% during the third quarter. Greenwich Wealth Management LLC now owns 16,475 shares of the company’s stock valued at $133,000 after purchasing an additional 1,400 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Annovis Bio in the 2nd quarter worth $115,000. Finally, Cetera Advisors LLC bought a new stake in shares of Annovis Bio in the 1st quarter worth about $122,000. Institutional investors own 15.83% of the company’s stock.

Annovis Bio Company Profile

Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.